Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels.

The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Hedge fund aims to influence CEO appointment as drugmaker battles share price slump and competition from Eli Lilly.

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

Novo Nordisk cited market challenges and its declining share price in a press release announcing the leadership shake-up. Jørgensen will stay on as CEO temporarily for an undetermined period of ...

The company said Friday that Jorgenson led Novo Nordisk through "a significant growth journey and transformation." It said in his eight-year tenure as CEO the company's profits, share price and ...

In a statement, Novo Nordisk said that finding a new CEO is in the best interests of the company and its shareholders considering "recent market challenges, the share price decline, and the wish ...